Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 174

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 174
---
4%       |
| Of which new launches (*)                   |       2,237 | +145.3%     | +135.2%          |        1,533 | +156.7%     |    491 | +129.3%     |              213 | +113.3%     |

| 82 | SANOFIFORM 20-F2024 |

| PART I                                               |
| ITEM 5. Operating and Financial Review and Prospects |

3/ Net sales – Biopharma segment In 2023 , net sales for the Biopharma segment amounted to € 37,817 million, up 0.4% on a reported basis and 5.4% at CER. Comments on the performances of our major Biopharma segment products are provided below. New launches ALTUVIIIO , a first-in-class, once-weekly factor VIII replacement therapy that confers significant protection against bleeds for hemophilia A patients, was launched in the United States at the end of March 2023 and generated sales of € 159 million in 2023 . Sales of Nexviazyme/Nexviadyme reached € 425 million, including € 272 million in the United States, reflecting switches of eligible Pompe patients (advanced stage) from Myozyme/Lumizyme and increased uptake by new patients. Net sales of Rezurock reached € 310 million, a significant increase of 54.6% CER. Since its launch, approximately 4,000 patients have been treated, with strong persistency rates. Sanofi recently reacquired rights to be the sole marketing authorization holder for Rezurock in China, where in August 2023 the China National Medical Products Administration (NMPA) approved belumosudil (Rezurock) for the treatment of patients aged 12 years and older with chronic Graft Versus Host Disease (cGVHD) who have an inadequate response to corticosteroids or other systemic treatments. Net sales of Sarclisa (multiple myeloma) in 2023 were € 381 million, up 37.1% CER , with good performances in all three regions: the United States (€ 165 million, + 33.9% CER); Europe (€ 111 million, + 27.3% CER); and the Rest of the Word, especially Japan where sales reached €77 million (+ 28.8% CER). Cablivi posted